



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# بسم الله الرحمن الرحيم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكرو فيلم



# شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



### يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**MONA MAGHRABY**



# **Genetic Polymorphism of Selected Genes as Susceptible Risk Factors in the Progression of Hepatitis C Viral Infection to Hepatocellular Carcinoma**

**Submitted By**

**Hany Mohammed Mohammed Abdel Allah**

M.Sc. (2014) in Biochemistry

Medical Research Institute, Alexandria University

**For the Fulfillment of the PhD Degree in Biochemistry**

*Under supervision of*

**Prof. Dr. Walid E. Zahran**

Professor of Biochemistry

Faculty of Science

Ain Shams University

**Prof. Dr. Samir A.M. El-Masry**

Professor of Biochemistry and Molecular Biology

Genetic Engineering and Biotechnology Institute

University of Sadat City

**Prof. Dr. Mahmoud M. El-Bendary**

Professor of Tropical Medicine and Hepatology

Faculty of Medicine

Mansoura University

**Dr. Ahmed F. Soliman**

Associate Professor of Biochemistry

Faculty of Science

Ain Shams University

Biochemistry Department

Faculty of Science

Ain Shams University

2021



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

(قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا  
مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ  
الْحَكِيمُ)

صدق الله العظيم  
البقرة - الآية ٣٢

**Ain Shams University**  
**Faculty of Science**

<b>Name</b>	: Hany Mohammed Mohammed
<b>Scientific Degree</b>	: Ph.D. in Biochemistry
<b>Department</b>	: Biochemistry
<b>Faculty</b>	: Science
<b>University</b>	: Ain Shams
<b>Graduation Year</b>	: 2005
<b>Master's degree Year</b>	: 2014
<b>Grant Year</b>	: 2021

*I declare that this thesis has been composed by myself and the work herein has not been submitted for a degree at this or any other university.*

*Hany Mohammed Mohammed*

## **Acknowledgment**

*First of all, I offer thanks always to ALLAH, for his great care and guidance in every step of my life and for giving me the ability to complete this work and who made all things possible.*

*It was a great pleasure for me to express my deep gratitude and appreciation to **Prof. Dr. Walid E. Zahran**, Professor of Biochemistry, Faculty of Science, Ain Shams University, for his continuous guidance, advice and supervision and sacrificing a lot of his precious time to revise each and every step of this study. It is hard for me to find the appropriate words that would do his favors.*

*I am deeply indebted to **Prof Dr. Samir A.M. El-Masry**, Professor of Biochemistry and Molecular Biology, Genetic Engineering and Biotechnology Institute, University of Sadat City, for his kind supervision, Continuous support, help, encouragement, valuable guidance, care, and advice. I am very lucky to have this great opportunity to be one of his students.*

*My sincere thanks and great gratitude to **Prof. Dr. Mahmoud M. El-Bendary**, Professor of Tropical Medicine and Hepatology, Faculty of Medicine, Mansoura University, for his sincere guidance, generous help, encouragement and patience.*



*I would like to express my deep gratitude to **Dr. Ahmed F. Soliman**, associate Professor of Biochemistry, Faculty of Science, Ain Shams University, for his keen supervision and continuous assistance and constant support and encouragement are much appreciated. I am grateful in every possible way for his wise opinions and critical comments throughout the whole study and work.*

*I wish also to express my thanks to all my family for their endless support and unyielding faith in me and for their tolerance of my absence, physically and emotionally stress many, many thanks. The completion of this thesis would have never been conceivable without their fervent motivation.*

**Hany M. Mohammed**

## ***Abstract***

**Background:** Owing to the high infection prevalence of hepatitis C virus (HCV), hepatocellular carcinoma (HCC) is considered a major health problem in Egypt. Identification of host genetic factors influencing the risk of developing HCC in patients with HCV infection may help to refine patients' selection to benefit from specific preventative measures and/or adapted screening policies. Thus, the current study aimed to investigate the association of *MTHFR* C677T and A1298C in addition to *TS* 3'-UTR 1494del/ins 6bp polymorphisms with the susceptibility to HCV-related HCC in an Egyptian population.

**Method:** Genotyping of the polymorphisms under study was performed using polymerase chain reaction-restriction fragment length polymorphism in 90 HCV-related HCC patients, 104 HCV-cirrhotic patients, and 100 healthy controls.

**Results:** In healthy controls, the *MTHFR* C677T polymorphism under the homozygous codominant, recessive, and allelic models, the *MTHFR* A1298C polymorphism under all the genetic models, and *TS* polymorphism under the allelic model only were associated with an increased risk of HCC. In HCV patients, the *MTHFR* C677T polymorphism under all the genetic models, as well as both *MTHFR* A1298C and *TS* polymorphisms under the homozygous codominant model only, increased the susceptibility to HCC. The C/C and T/C haplotype combinations of *MTHFR* C677T and *MTHFR* A1298C polymorphisms conferred increased the risk for healthy subjects to develop HCC whereas, the T/C haplotype only contributed to increased susceptibility to HCC in HCV patients.

**Conclusion:** *MTHFR* C677T and A1298C in addition to *TS* 3'-UTR 1494del/ins 6bp polymorphisms may contribute to the development of HCV-related HCC in an Egyptian population. These findings may aid in the early diagnosis and management of HCC.

## *Contents*

List of tables .....	I
List of figures .....	III
List of abbreviations .....	IV
<b>Introduction</b> .....	VI
<b>Aim of the work</b> .....	X
<b>I. Review of Literature</b>	
1. Hepatocellular carcinoma .....	1
1.1. Incidence .....	2
1.2. Risk factors .....	5
1.2.1. Hepatitis .....	5
➤ <i>Hepatitis C virus infection</i> .....	6
I. HCV structure and pathogenicity .....	8
II. HCV and hepatocarcinogenesis .....	11
➤ <i>Hepatitis C virus infection</i> .....	15
I. HBV structure and pathogenicity .....	16
II. HCV mechanisms of hepatocarcinogenesis .....	19
1.2.2. Aflatoxin .....	21
1.2.3. Tobacco .....	22
1.2.4. Host-related risk factors .....	23
➤ <i>Obesity</i> .....	23
➤ <i>Nonalcoholic fatty liver disease</i> .....	23
2. Methylenetetrahydrofolate reductase .....	24
2.1. <i>MTHFR</i> mutations and polymorphisms .....	28
• <i>MTHFR</i> C677T .....	29
• <i>MTHFR</i> A1298C .....	29
2.2. Health risks associated with <i>MTHFR</i> polymorphisms .....	30
3. Thymidylate synthase .....	32
3.1. <i>TS</i> mutations and polymorphisms .....	34
<b>II. Subjects and Methods</b> .....	37
1. Subjects .....	37
1.1. Specimen collection .....	38
2. Methods .....	38
2.1. Biochemical analyses .....	38
2.1.1. Measurement of serum alanine transaminase activity .....	38
2.1.2. Measurement of serum aspartate transaminase activity .....	40

2.1.3. Measurement of serum albumin level .....	42
2.1.4. Measurement of serum total bilirubin level .....	44
2.1.5. Determination of serum alpha-fetoprotein level .....	45
2.2. Molecular analyses .....	48
2.2.1. Extraction of genomic DNA .....	48
2.2.2. Polymerase chain reaction .....	54
2.2.3. Agarose gel electrophoresis .....	58
2.2.4. Restriction fragment length polymorphism .....	60
2.3. Statistical analysis .....	62
<b>III. Results</b> .....	64
<b>IV. Discussion</b> .....	86
<b>V. Summary</b> .....	94
<b>References</b> .....	100
<b>Arabic Summary</b>	
<b>Arabic Abstract</b>	

### *List of Tables*

<i>Table No.</i>	<i>Subject</i>	<i>Page</i>
<b>1</b>	Primers' sequences of <i>MTHFR</i> and <i>TS</i>	<b>56</b>
<b>2</b>	Amplification profile	<b>58</b>
<b>3</b>	Basic characteristics of the study population	<b>65</b>
<b>4</b>	Genotype distribution and allele frequency of <i>MTHFR</i> C677T among different groups	<b>67</b>
<b>5</b>	Genotype distribution and allele frequency of <i>MTHFR</i> A1298C among different groups	<b>68</b>
<b>6</b>	Genotype distribution and allele frequency of <i>TS</i> 3'-UTR 1494del/ins 6 bp among different groups	<b>70</b>
<b>7</b>	Biochemical parameters among different polymorphic genotypes of <i>MTHFR</i> C677T gene polymorphism in control subjects	<b>71</b>
<b>8</b>	Biochemical parameters among different polymorphic genotypes of <i>MTHFR</i> C677T gene polymorphism in LC patients	<b>71</b>
<b>9</b>	Clinical and biochemical characteristics among different polymorphic genotypes of <i>MTHFR</i> C677T gene polymorphism in HCC patients	<b>72</b>
<b>10</b>	Biochemical parameters among different polymorphic genotypes of <i>MTHFR</i> A1298C gene polymorphism in control subjects	<b>73</b>
<b>11</b>	Biochemical parameters among different polymorphic genotypes of <i>MTHFR</i> A1298C gene polymorphism in LC patients	<b>74</b>
<b>12</b>	Clinical and biochemical characteristics among different polymorphic genotypes of <i>MTHFR</i> A1298C gene polymorphism in HCC patients	<b>74</b>
<b>13</b>	Biochemical parameters among different polymorphic genotypes of <i>TS</i> 3'-UTR 1494del/ins 6bp gene polymorphism in control subjects	<b>76</b>
<b>14</b>	Biochemical parameters among different	<b>76</b>

	polymorphic genotypes of <i>TS</i> 3'-UTR 1494del/ins 6bp gene polymorphism in LC patients	
<b>15</b>	Biochemical parameters among different polymorphic genotypes of <i>TS</i> 3'-UTR 1494del/ins 6bp gene polymorphism in HCC patients	<b>77</b>
<b>16</b>	<i>MTHFR</i> C677T polymorphism and HCC risk against control group according to the genetic association models	<b>78</b>
<b>17</b>	<i>MTHFR</i> C677T polymorphism and HCC risk against LC patients according to the genetic association models	<b>79</b>
<b>18</b>	<i>MTHFR</i> A1298C polymorphism and HCC risk against control group according to the genetic association models	<b>80</b>
<b>19</b>	<i>MTHFR</i> A1298C polymorphism and HCC risk against LC patients according to the genetic association models	<b>81</b>
<b>20</b>	<i>TS</i> 3'-UTR 1494del/ins 6bp polymorphism and HCC risk against control group according to the genetic association models	<b>82</b>
<b>21</b>	<i>TS</i> 3'-UTR 1494del/ins 6bp polymorphism and HCC risk against LC patients according to the genetic association models	<b>82</b>
<b>22</b>	Frequencies of <i>MTHFR</i> C677T and <i>MTHFR</i> A1298C haplotypes in the control and HCC groups as well as their association with HCC risk	<b>84</b>
<b>23</b>	Frequencies of <i>MTHFR</i> C677T and <i>MTHFR</i> A1298C haplotypes in LC and HCC groups as well as their association with HCC risk	<b>85</b>



### *List of Figures*

<b><i>Fig. No</i></b>	<b><i>Title</i></b>	<b><i>Page</i></b>
<b>1</b>	Progressive stages of liver disease to hepatocellular carcinoma (HCC) development	<b>2</b>
<b>2</b>	Global variations in age-adjusted incidence rates of liver cancer, and the prevalence of chronic HCV and HBV infections	<b>4</b>
<b>3</b>	HCV: model structure and genome organization	<b>10</b>
<b>4</b>	Estimation of worldwide prevalence of chronic hepatitis B virus	<b>16</b>
<b>5</b>	Hepatitis B virus (HBV) genome map	<b>18</b>
<b>6</b>	MTHFR metabolic pathway	<b>27</b>
<b>7</b>	Organization of human methylenetetrahydrofolate reductase (MTHFR) gene	<b>28</b>
<b>8</b>	Localizations of some of the SNPs studied in the <i>MTHFR</i> gene	<b>28</b>
<b>9</b>	Mechanism of thymidylate synthase inhibition by 5-fluorouracil	<b>34</b>
<b>10</b>	Regulation of <i>TS</i> gene expression	<b>36</b>
<b>11</b>	Calibration curve for serum AFP	<b>48</b>
<b>12</b>	Polymerase chain reaction	<b>55</b>
<b>13</b>	Detection of the studied variants' genotypes using agarose gel electrophoresis after performing polymerase chain reaction-restricted fragment length polymorphism (PCR-RFLP)	<b>66</b>
<b>14</b>	Plot and pairwise estimates of linkage disequilibrium in the study population	<b>83</b>